Multitude of opportunities for Finnish pharmaceutical industry in India
|
|
- Toby McDaniel
- 8 years ago
- Views:
Transcription
1 1 Multitude of opportunities for Finnish pharmaceutical industry in India Dr. Esa Heinonen, MD, PhD Senior Advisor Business Development and Support Orion Pharma
2 2
3 3 Challenges of pharmaceutical industry The R&D costs are increasing, but output of new NCEs is not Science is moving fast, but making a drug based on genomic information may take decades Regulatory requirements are continuously becoming more stringent, also post marketing commitments (pharmacovigilance) Pricing pressures for NCE are getting tougher (health economic evaluations) Patents are being challenged earlier, high costs of legal activities The price of older, generic products is getting lower than ever, cost of goods is becoming challenging
4 4 INDIA Population 1.1 billion Area 3.2 mkm 2 (7th in the world) Largest democracy in the world 23 languages, official languages English and Hindi Pharmaceutical market 9 b$ in 2006 (80 % generic), annual growth 11 % About 300 million people in growing middle class, GDP growth 6-8 % annually
5 5 Why to India? Large pool of well educated experts in pharmaceutical fields (especially in chemistry, galenics, process development, manufacturing, medicine) with good IT skills (> scientists annually, PhDs in chemistry) Lower costs of man power for R&D and manufacturing, contract manufacturing (CMO) and research organisations (CRO) are well developed in India: manufacturing costs about 20 % research 10-30% clinical development 50 % of the costs in Western Europe or USA Adequate quality in GMP: India has the highest number of FDA approved manufacturing facilities (>60 ) outside USA, India produces more than 20 % of world s generic products!
6 6 Why to India? Communication easy in English Due to large population a significant pool of untreated patients available with vast genetic diversity, high level cliniques Rapidly improving skill sets in biotechnology and drug discovery, new research centers are being built (annual turnover of biotech products 700 m$ in 2004, 5 b $ in 2010?) India presents 20 % of the global drug markets by volume, but only 1 % by value, a significant increase of value is expected (over 20b$ in 2010?) Tax benefits available for foreign investments (SEZ etc.), especially for R&D work
7 7 Trends and challenges in Indian pharma sector (1) There are pharma companies, 3000 involved in production, but 250 leading companies control 70 % of India s market, consolidation is expected to take place, opportunities for M&As emerge The strategy of Indian pharma companies seems to be to launch the products first in India and the neighbouring countries, then Latin America, Africa, CIS, the USA and finally the EU Indian companies are acquiring companies in the USA and Europe Competition with Chinese API manufacturers
8 8 Trends and challenges in Indian pharma sector (2) IPR: Patent Acts 2005 meets the requirements of TRIPS (Trade related Aspects of Intellectual Property), medicines invented after 1995 are protected, how will this work in practice? When the patent legislation will start to work, there will be less generic opportunities Are there sufficiently competencies to be able to develop NCEs, and willingness to take the risks? Spin off of discovery and development of NCEs to independent companies, generic companies do not want to take the risk (?), codevelopment joint ventures available The salaries of academically qualified persons are increasing fast
9 9 Trends and challenges in Indian pharma sector (3) Prices in the Indian market are generally very low, competition is fierce, how to bring European drugs into the Indian market? How will the reimbursement system work? Development of health insurance system? More than 300 million people living below the poverty line, only 5 % of GDP spent on health care, per capita spending of pharmaceuticals is 4$ (796 $ in USA, 322$ in the UK) The infrastructure of the society should be improved (traffic, power and water supply) Ethical issues in clinical studies (low literacy rate, consent) Some extra byrocracy exists (e.g. import licences)
10 Business Areas of Orion Corporation 10 Pharmaceuticals- Orion Pharma Proprietary Products (patented prescription products) Specialty Products (off-patent prescription products and Animal Health self-medication products) Pharmaceutical Ingredients (API s, Fermion) Diagnostic Tests Orion Diagnostica The turnover in 2007 was 684m, profit 196 m R&D 98 m (14 % of turnover), personnel 3176
11 11 Innovations to the market from Orion s R&D Over its long history, Orion has invented and been the first to introduce many new products to the pharmaceutical market. Since the 1980 s, e.g. the following proprietary products have been launched: Product Launch year Indication Stalevo 2003 Parkinson s Disease Simdax 2000 Acute Heart Failure Precedex 1999 Intensive care sedative Comtan/ Comtess Indivina, Divina, Diviseq, Divigel 1998 Parkinson s Disease Menopause Fareston 1988 Breast cancer Antisedan, Domitor & Domosedan Animal sedatives
12 Clinical studies carried out by Orion in any country focus in Europe 12
13 Establishing the liaison office in India 13 The legal process took four months (9-12/07), opening a bank account required at least as much paper + stamps Recruitement took 3 months Not too many good options to rent an office space in Mumbai Finpro was a great help to us!
14 Finnish companies in India 14 Pöyry Andritz StoraEnso Incap Sandvik TietoEnator Metso Automation, Minerals & Paper Wärtsilä Finnair Huhtamäki / PPL Finarte Exomi Ecocat ORION Nethawk M-Real F-Secure Citec Tekla Elcoteq Nokia Production/R&D Sales/Rep.office Aspocomp Salcomp Perlos Vacon Kone
15 15 Orion in India Discovery cooperation (e.g. Aurigene) Sourcing of active pharmaceutical ingredients and intermediates In-licencing of selected generic products Development of selected older generic products Marketing diagnostic products through a partner Screening for new business opportunities with pharma companies and CROs, assuring timely delivery and quality of the products
16 16 Strategic partnerships/joint ventures Long term commitments between Orion and selected Indian companies Balanced business model providing win-win deals is the cornestone of the long-term relationship Orion can offer: a reliable partner in Europe knowledge of the regulatory requirements of generic and proprietary products in EU and how to get into the market drug discovery and development knowledge of proprietary molecules sharing of the risk development of drug candidates marketing rights of its proprietary or generic products for India
17 17 Our experiences with Indian companies Price levels are usually very competitive, but some companies offer services at a rate similar to European CROs Great variability in quality, but the FDA approved sites usually are excellent, strong USA focus in documentation Following time tables is sometimes too flexible, there are production planning needs Discovery cooperation has been excellent Getting import licences cause delays in R&D work Fast turnover of staff In family owned companies the desicion making is fast Some larger Indian companies may feel they do not need a partner in Europe as they already have daughter companies established there
18 18 Induction program in Espoo ( 2)
19 19
Orion s Annual Report 2008
Orion s Annual Report 2008 Dear reader, Orion s Annual Report 2008 comprises two sections: Company Brochure and Financial Statements. The Brochure section includes a Well-Being Guide with tips for a healthier
More informationOur net sales were at similar level to the previous year and as expected our operating profit was slightly lower than in 2012.
ORION CORPORATION / INTERIM REPORT / JANUARY JUNE 2013 / at 12:00 noon EEST Orion Group Interim Report January June 2013 Orion s net sales in January June 2013 totalled EUR 497 million (EUR 480 million
More informationPresented at: Jefferies 2015 Global Healthcare Conference
Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution
More informationEmerging Clinical Sites: India and China. Patrycja Doba, Clinical Research Coordinator
Emerging Clinical Sites: India and China Patrycja Doba, Clinical Research Coordinator Overview 1. Outsourcing trends in Pharmaceutical Industry 2. Reasons for outsourcing 3. The most outsourced activity
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationOPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY
NINESIGMA WHITE PAPER OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY How six leading healthcare companies are leveraging Open Innovation to achieve their innovation goals By: Stephen Clulow, Director
More informationSTATS WINDOW. INDUSTRY REVIEW AT A GLANCE Global Pharmaceutical Industry
Volume 6, Issue 6, December 2013 STATS WINDOW The Pacific Business Review International has taken an initiative to start a section which will provide a snapshot of major Global & Indian economic indicators
More informationIndian Markets and Economics
Indian Markets and Economics Find 2008 Global Innovation Summit Oulu 29.5.2008 Finpro Intia 2008 / Finpro ry / 2 Finpro in India New Delhi 6 (+1) persons Mumbai 4 persons Chennai 2 (+2) persons / Finpro
More informationHealthcare Innovation in the UK - A Royal Society of Chemistry Position Paper
Healthcare Innovation in the UK - A Royal Society of Chemistry Position Paper Introduction The pharmaceutical industry (Pharma) has made important contributions to quality of life, longevity, economic
More informationCOMPANY BROCHURE 2007
COMPANY BROCHURE 2007 Orion Orion Corporation is a Finnish stock exchange company which develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global
More informationEven we will get to use your product someday. Enough reason for us to deliver.
Even we will get to use your product someday. Enough reason for us to deliver. ClinInvent: Putting our heart and soul behind the research. At ClinInvent, when we talk about clinical research it s not just
More informationCOMPANY BROCHURE 2007
COMPANY BROCHURE 2007 Orion Orion Corporation is a Finnish stock exchange company which develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global
More informationAn Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore
An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore A CanBiotech Report CanBiotech, 2007 1 An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight
More informationContents. Parent company Orion corporation s financial statements (FAS)... 126 Proposal by the Board of Directors on use of profit...
Annual Report 2011 Contents Orion in 2011... 1 CEO s Review... 1 Orion in brief... 4 Key figures... 6 2011 in brief... 10 Business environment...11 Strategy... 12 Business divisions in 2011... 18 Proprietary
More informationMSc program Pharmaceutical Design and Engineering. Peter Heegaard, Head of Studies DTU Veterinary
MSc program Peter Heegaard, Head of Studies DTU Veterinary There is a need for Pharma graduates Pharma industry in its widest sense (see next slide) Research institutions (public and private) Consultants
More informationTo 2012 and onwards. Orion CMD 2009. Orion Capital Markets Day 1 December 2009 in Helsinki. Coffee break. Lessons learned from recent market entries
To 2012 and onwards Orion Capital Markets Day 1 December 2009 in Helsinki To 2012 and onwards Orion CMD 2009 9:05 Orion in change Timo Lappalainen CEO Targeting selected therapy areas Liisa Hurme SVP,
More informationCFO s presentation. CFO Jari Karlson
CFO s presentation CFO Jari Karlson Orion s financial objectives Increasing net sales. Achievement of this objective requires continuous investment in development of the product portfolio. Maintaining
More informationRegulatory Considerations for Conducting Clinical Trials In India
Regulatory Considerations for Conducting Clinical Trials In India By Mukesh Kumar, PhD & Surinder Kher, MD In the last few years, there has been increasing interest in the pharmaceutical industry in outsourcing
More information2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life
More informationClinical Supply Chain Management - Technologies such as IVRS, CTMS, EDC and RFID Enhance Drug Supply Management
Brochure More information from http://www.researchandmarkets.com/reports/2226324/ Clinical Supply Chain Management - Technologies such as IVRS, CTMS, EDC and RFID Enhance Drug Supply Management Description:
More informationProfile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many
More informationHow companies leverage quality and quality certifications to achieve competitive advantage
How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for
More informationBrochure More information from http://www.researchandmarkets.com/reports/2011199/
Brochure More information from http://www.researchandmarkets.com/reports/2011199/ Healthcare BPO Market - Payer (Claims Processing), Provider (Medical Billing & Coding) & Pharmaceutical (Clinical Trial
More informationBrand Quality with Asian Advantages
Brand Quality with Asian Advantages ScinoPharm Taiwan, Ltd. No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan TEL : 886-6-505-2888 FAX : 886-6-505-2898 Email Contact : mkt@scinopharm.com
More informationWhy Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
More informationU.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010
U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction
More informationBiomedical Business: Current Trends, Product Challenges and Future Outlook
Biomedical Business: Current Trends, Product Challenges and Future Outlook Prepared and Presented by Audrey S. Erbes, Ph.D. Principal, Erbes & Associates Life Science Marketing and Business Development
More informationNEW CHEMICAL ENTITIES
NEW CHEMICAL ENTITIES PIONEERING PARTNER FOR PEPTIDES With more than 40 years of expertise in peptide synthesis, a track record in process development, large-scale manufacturing and outstanding product
More informationJob Profile Clinical Research Associate III (CRA)
PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed
More informationSalary Survey 2014. Domestic, International Salary Survey and Country Cost Analysis
Salary Survey 2014 Domestic, International Salary Survey and Country Cost Analysis Disclaimer: This salary guides contained herewith have been constructed to represent average salaries across a range of
More informationJoin our scientific talent community
Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into
More informationClinical Research in Mauritius
BOARD OF INVESTMENT Clinical Research in Mauritius This document provides an informative summary of the procedure to apply for a clinical research protocol in Mauritius. Contents INTRODUCTION... 2 I. APPLICATION
More informationTechnology Policy and Management Course 38E00100 "Immaterial Property Rights", Spring 2007, 1st Period. IMMATERIAL PROPERTY SYSTEM 31st January 2007
Helsinki School of Economics Technology Policy and Management Course 38E00100 "Immaterial Property Rights", Spring 2007, 1st Period IMMATERIAL PROPERTY SYSTEM 31st January 2007 WELCOME! Olli Ilmarinen,
More informationA Texas Life Science Perspective. Thomas R. Kowalski President Texas Healthcare and Bioscience Institute
A Texas Life Science Perspective Thomas R. Kowalski President Texas Healthcare and Bioscience Institute 1 What is THBI? The Texas Healthcare and Bioscience Institute (THBI) is a non-profit, public policy
More informationPromoting innovation and improving access
NATIONAL ASSESSMENT TOOL TO ASSIST MEMBER STATES IN IMPLEMENTING THE GLOBAL STRATEGY AND PLAN OF ACTION ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY Promoting innovation and improving access
More informationUK- India Science Bridge: BioPharm 2020
DST INDIA - RESEARCH COUNCILS UK UK- India Science Bridge: BioPharm 2020 Entrepreneurial Opportunities for Indian and UK Scientists in the Pharmaceutical and Biotechnology Industries UK-India Impact Symposium
More informationPATENT ISSUES & LOCAL PHARMACEUTICAL PRODUCTION IN GHANA. By Kwasi Poku Boateng QUALITY MANAGEMENT CONSULTANT
PATENT ISSUES & LOCAL PHARMACEUTICAL PRODUCTION IN GHANA By Kwasi Poku Boateng QUALITY MANAGEMENT CONSULTANT International Conference on Local Pharmaceutical Production in Africa, Cape Town, April 4-6,
More informationIn-depth analysis of the report is based on propriety databases, primary and secondary research and inhouse analysis by a team of experts.
Brochure More information from http://www.researchandmarkets.com/reports/1882193/ Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising
More informationInformatics and Knowledge Management at the Novartis Institutes for BioMedical Research (NIBR)
Informatics and Knowledge Management at the Novartis Institutes for BioMedical Research (NIBR) Enable Science in silico & Provide the Right Knowledge to the Right People at the Right Time to enable the
More informationFramework for rapid assessment of the pharmaceutical sector in a given country
Framework for rapid assessment of the pharmaceutical sector in a given country Prepared for Flagship Course (Health) Glossary: EU GLP GMP HIF IMS INN MOH NGO OEBIG OECD OTC PER R&D Rx TRIPS VAT WHO European
More informationPrivate Healthcare. How To Apply For IFC Financing About IFC CREATING OPPORTUNITY IN EMERGING MARKETS
How To Apply For IFC Financing About IFC A company or entrepreneur seeking to establish a new health project or expand an IFC, a member of the World Bank Group, is the largest global development existing
More informationInnovative people need room to breathe
92/93 Arthur D. Little How important is the protection of intellectual property to sustaining innovation in your business? Schwan Without patents there would be no innovation in our industry. Patents are
More informationMedicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia
Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationSWOT ANALYSIS OF INDIAN PHARMACEUTICAL INDUSTRY
SWOT ANALYSIS OF INDIAN PHARMACEUTICAL INDUSTRY KAPIL KUMAR*; DR. M. K. KULSHRESHTHA** *RESEARCH SCHOLAR, BHAGWANT UNIVERSITY, AJMER ** DIRECTOR, S. D. COLLEGE OF MANAGEMENT, PANIPAT ABSTRACT The global
More informationHOT TOPICS IN IN HEALTH CARE REFORM
By Felicia Fuller Publications Manager, DAC Patient Recruitment Services The Patient Protection and Affordable Care Act (ACA), colloquially known as Obamacare, is in full effect and its impact is palpable
More informationMarieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014
Coming together is a beginning, keeping together is progress, working together is success. - Henry Ford - Considering the clinical research industry as an area for enhanced public-private sector collaboration
More informationEDITORIAL MINING FOR GOLD : CAPITALISING ON DATA TO TRANSFORM DRUG DEVELOPMENT. A Changing Industry. What Is Big Data?
EDITORIAL : VOL 14 ISSUE 1 BSLR 3 Much has been written about the potential of data mining big data to transform drug development, reduce uncertainty, facilitate more targeted drug discovery and make more
More informationInstitute for OneWorld Health
Institute for OneWorld Health a nonprofit pharmaceutical company Oxymoron no more: nonprofits can deliver medicines for the poor of the world January 10, 2005 Victoria Hale, PhD CEO, OneWorld Health The
More informationHealthcare, Regulatory and Reimbursement Landscape - Australia
Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape
More informationA Portrait of the Enterprise Software User in the Pharmaceutical Industry
A Portrait of the Enterprise Software User in the Pharmaceutical Industry Rahim Kaba - 1/4/2012 4:44:00 PM My article depicting a portrait of the Indian enterprise software user prompted me to develop
More informationThe Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry
Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge
More informationMaking the most of academic drug target discoveries
Making the most of academic drug target discoveries Richard Reschen, Isis Innovation, University of Oxford The explosion of new technologies and research techniques, and encouragement from funding agencies
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationGlobalization of Clinical Trials Promise and Reality
Globalization of Clinical Trials Promise and Reality Zvi Ladin, Ph.D. Boston MedTech Advisors www.bmtadvisors.com November 2008 1 Outline Ethical principles Historical perspective Registration requirements
More informationNURSE & ALLIED STAFFING CLINICAL TRIALS SERVICES EDUCATION & RETAINED SEARCH
NURSE & ALLIED STAFFING CLINICAL TRIALS SERVICES EDUCATION & RETAINED SEARCH May 2008 This presentation contains forward-looking statements. Statements that are predictive in nature, that depend upon or
More informationRNCOS Online Business Research
RNCOS Page 1 of 18 About Us RNCOS, formed in the year 2002, aims to outsource all your business needs and serve your customers in their quest for the information. RNCOS is transforming the concept of Outsourcing
More informationGeneral Legal Service Provider Information Form
General Legal Service Provider Information Form General information Name of Organisation LK Shields Solicitors Contact information Head of Organisation: Hugh Garvey (Managing Partner) Name: LK Shields
More informationProfile of Biomedical Research and Biotechnology Commercialization. Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Boston Along with San Francisco,
More informationTACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES
TRANSATLANTIC CONSUMER DIALOGUE WASHINGTON MEETING, 10-12 FEBRUARY 2000 TACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES The Commission Services
More informationThe majority of pharmaceutical companies in
Pharmaceutical Infrastructure and Industry Professor Che-Ming Teng, Ph.D. National Taiwan University College of Medicine, Taipei, Taiwan The majority of pharmaceutical companies in Taiwan are devoted to
More informationVectura Group plc. Annual Report and Accounts 2015
RNS Number : 1783Q Vectura Group plc 15 June 2015 15 June 2015 Vectura Group plc Annual Report and Accounts 2015 In accordance with the Listing Rule 9.6.1, a copy of the following document has been submitted
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More informationEROSION OF EXCLUSIVE MARKETING RIGHTS- BOON FOR THE PHARMACEUTICAL SECTOR
IPR & TECHNOLOGY BULLETIN EROSION OF EXCLUSIVE MARKETING RIGHTS- BOON FOR THE PHARMACEUTICAL SECTOR Contents Introduction...2 1. What is EMR?...2 2. Provisions of TRIPS...3 2.1 TRIPS and India s compliance...3
More informationProduction in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation
Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Industry Studies Association Pittsburgh, June 1, 2011 Elisabeth Reynolds, Ph.D.
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationPharmAssess Audit Reports Operational Consultancy GMP Auditing Services Regulatory Affairs. www.rephine.com
PharmAssess Audit Reports Operational Consultancy GMP Auditing Services Regulatory Affairs www.rephine.com The Market Leader in GMP Audit Reporting PharmAssess audit reports are accepted by all Regulatory
More informationHealth and Health Care in India Policy implications for Europe
Health and Health Care in India Policy implications for Europe David Taylor Professor of Pharmaceutical and Public Health Policy University College London School of Pharmacy Dr Jennifer Gill Research Fellow
More informationACC San Diego Chapter
ACC San Diego Chapter Biomedical and Technology Collaborations with Chinese Companies: Legal and Cultural Challenges October 2012 DLA Piper Overview Our Firm 4,200 lawyers in 77 offices and 33 countries
More informationPharmaceutical Markets in Latin American Countries. Chris Swann Espicom Business Intelligence
Pharmaceutical Markets in Latin American Countries Chris Swann Espicom Business Intelligence Contents Demographics Economic factors Pharmaceutical market characteristics Summary - Overview of markets VENEZUELA
More informationFINLAND ON A ROAD TOWARDS A MODERN LEGAL BIOBANKING INFRASTRUCTURE
Postrefereed, preprint version of the text published at European Journal of Health Law 2013(3)28994. Link to the publisher s website: http://www.brill.com/europeanjournalhealthlaw Sirpa Soini FINLAND ON
More informationPIRAMAL DISCOVERY SOLUTIONS
PIRAMAL DISCOVERY SOLUTIONS Pharma Solutions products and services Delivering Globally Integrated Solutions across the drug lifecycle We are the Contract Development & Manufacturing arm of Piramal Healthcare,
More informationProfile of Biomedical Research and Biotechnology Commercialization. Washington-Baltimore Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization Washington-Baltimore Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Washington-Baltimore The Washington,
More informationGlobal Wellness Technology Business. High Potential for Future Success. Pasi Sorvisto 25.11.2005
Global Wellness Technology Business High Potential for Future Success Pasi Sorvisto 25.11.2005 What kind of Business we are talking about? Spending on healthcare in U.S. is 14% and in Europe 8,5% of GDP.
More informationFuture Specialisation for Pharmacists in Industry
Future Specialisation for Pharmacists in Industry JANE NICHOLSON Executive Director European Industrial Pharmacists Group (EIPG) Innovation gap... Cost is now ~ 700-1billion Success Rate 1 in 10,000 By
More informationImplementing EDC in emerging global regions. Nermeen Varawalla, MD, PhD, MBA Vice President, Corporate Development PRA International
Implementing EDC in emerging global regions Nermeen Varawalla, MD, PhD, MBA Vice President, Corporate Development PRA International East Coast Annual EDC & Beyond, November 2006 Agenda: EDC for clinical
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationOpen Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum
Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities
More informationOutsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis
Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Paulina Ramirez: Birmingham Business School IRIMA Workshop on the Internationalisation
More informationVTT Technical Research Centre of Finland 2010
VTT Technical Research Centre of Finland 2010 02/04/2010 2 GDP share of R&D expenditure in Finland % 3 3.43 3.45 3.48 3.45 3.47 3.72 3.92 2.1 1990 1998 2003 2004 2005 2006 2007 2008 2009 Source: Statistics
More informationMarket Insights Life Sciences
Market Insights Life Sciences Key Facts Scotland hosts the UK s second largest life sciences cluster and one of the most sizeable in Europe. The life sciences sector contributes 3.1 billion turnover and
More informationScience Technology and Innovation in Sri Lanka
THE PANEL OF THE UNITED NATIONS COMMISSION ON SCIENCE AND TECHNOLOGY FOR DEVELOPMENT 28-30 November 2007 Kuala Lumpur Science Technology and Innovation in Sri Lanka The views presented here are the participants
More informationDrug Development Models in China and the Impact on Multinational Pharmaceutical Companies
Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial
More informationDear Business Development or Corporate Alliance Director/Manager,
Korea Drug Research Association(KDRA) and Korea Health Industry Development Institute(KHIDI) cordially request the potential global outsourcing partners(cros, CMOs, CSOs & Consulting Firms) having contract
More informationGMP Pharma BV. Netherlands
GMP Pharma BV Netherlands Connecting the European & Indian Pharmaceutical, Biotechnology and Biopharmaceutical Industry for parallel growth and solicitation. About Us: GMP Pharma BV is a multisource organization
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationNAHU. The Role of the Health Insurance Professional in Educating America. by Scott Leavitt. NAHU President
NAHU The Role of the Health Insurance Professional in Educating America by Scott Leavitt NAHU President Introduction To help licensed agents, brokers & consultants understand that they have a serious responsibility
More informationDZIF-Product Development Unit (PDU)
November 29, 2013 7 th International VPM Days DZIF-Product Development Unit (PDU) - DZIF-TPMO at HZI - DZIF-OSRA at PEI Thomas Hesterkamp, Helmholtz Zentrum für Infektionsforschung Support from TPMO &
More informationThe agency perspective: What we do and how we do it
The agency perspective: What we do and how we do it Tim Ryder and Olga Dai 15 July 2011 Who are we? Tim Ryder Scientific Team Leader, Darwin HC MA in Biochemistry; DPhil in Physiology 10 years of experience
More informationCAREERS IN PHARMACY. Contrary to popular perception, a career in pharmacy is not only challenging but lucrative as well says Dr. U.B.
CAREERS IN PHARMACY Contrary to popular perception, a career in pharmacy is not only challenging but lucrative as well says Dr. U.B. Hadkar Traditionally a qualification in Pharmacy was associated with
More informationCurriculum Vitae. Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details. Education
Curriculum Vitae Prof. Dr. Bernhard Kutscher, Ph.D. Personal Details Private Address: Date, Place of Birth: Marital Status: Nationality: Languages: Stresemannstraße 9, 93477 Maintal, Germany, Tel. +49
More informationTriskel: a strategic consulting firm for biopharmaceutical companies
BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland
More informationThe Pharmaceutical Manufacturing Plan for Africa Business Plan (PMPA BP)
IPC Meeting, World Bank, Washington D.C., 11-12 Dec 2012 The Pharmaceutical Manufacturing Plan for Africa Business Plan (PMPA BP) Juergen Reinhardt Project Manager Business, Investment and Technology Services
More informationTABLE OF CONTENTS International Transfer Pricing in the Ethical Pharmaceutical Industry Second edition
TABLE OF CONTENTS International Transfer Pricing in the Ethical Pharmaceutical Industry Second edition SUMMARY OF SALIENT POINTS Importance and Competitiveness of the Ethical Pharmaceutical Industry Government
More informationWhat Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
More informationAn integrated global healthcare company
An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment
More informationOPPI Monitor Group Collaboration. Outsourcing Opportunities in Indian Pharmaceutical Industry
AMSTERDAM ATHENS BEIJING CAMBRIDGE CHICAGO FRANKFURT HONG KONG ISTANBUL JOHANNESBURG LONDON LOS ANGELES MADRID MANILA MILAN MOSCOW MUMBAI MUNICH NEW YORK PARIS SAN FRANCISCO SÃO PAULO SEOUL SINGAPORE STOCKHOLM
More informationWhen treating a disease is bad business: orphan and neglected diseases
When treating a disease is bad business: orphan and neglected diseases Rocío Acuña Hidalgo Introduction Over the past decades, the development of thousands of new drugs to treat diseases has improved the
More informationClinical Research Associate (CRA) - A Growing Career Path in Biotechnology / Pharmaceutical Industry
Clinical Research Associate (CRA) - A Growing Career Path in Biotechnology / Pharmaceutical Industry By http://www.clinicalresearchassociate cra.com/studyguide/ A clinical research associate (CRA) is a
More informationGLOBAL ACCESS LICENSING FRAMEWORK
GLOBAL ACCESS LICENSING FRAMEWORK Every university-developed technology with potential for further development into a drug, vaccine, or medical diagnostic should be licensed with a concrete and transparent
More information